Table 2.
Baseline demographics and clinical characteristics of the study population
| Subject | Age (Yr) | Sex | Race | BMI | Montelukast (Y/N) | Lifetime polypectomies (No.) | ICS Use (mcg/day)* |
|---|---|---|---|---|---|---|---|
| 01 | 31 | F | White | 19.46 | N | 3 | 0 |
| 02 | 33 | F | White | 19.79 | N | 1 | 0 |
| 03 | 44 | F | White | 29.42 | Y | 7 | 1760 |
| 04 | 57 | M | White | 26.23 | Y | 2 | 0 |
| 05 | 55 | F | Black | 33.47 | Y | 1 | 940 |
| 06 | 65 | F | Black | 22.36 | Y | 2 | 1240 |
| 07 | 46 | F | White | 20.48 | N | 1 | |
| 08 | 59 | F | White | 23.93 | Y | 1 | 220 |
| 09 | 63 | F | White | 30.95 | N | 200 | |
| 10 | 54 | F | White | 23.68 | Y | 2 | 320 |
| Median | 54.5 | – | – | 23.81 | – |
*
ICS use is calculated as fluticasone equivalent dose.